Misplaced Pages

Revision as of 19:28, 28 January 2016

Pathogenic Escherichia coli
Scientific classification
Domain:	Bacteria
Phylum:	Proteobacteria
Class:	Gammaproteobacteria
Order:	Enterobacteriales
Family:	Enterobacteriaceae
Genus:	Escherichia
Species:	E. coli
Binomial name
Escherichia coli (Migula 1895) Castellani and Chalmers 1919
Synonyms
Bacillus coli communis Escherich 1885

Escherichia coli (/ˌɛʃəˈrɪkiə ˈkoʊlɪ/ Anglicized to /ˌɛʃəˈrɪkiə ˈkoʊlaɪ/; commonly abbreviated E. coli) is a gram-negative, rod-shaped bacterium that is commonly found in the lower intestine of warm-blooded organisms (endotherms). Most E. coli strains are harmless, but some serotypes are pathogenic and can cause serious food poisoning in humans, and are occasionally responsible for product recalls. The harmless strains are part of the normal flora of the gut, and can benefit their hosts by producing vitamin K₂, and by preventing the establishment of pathogenic bacteria within the intestine.

Introduction

E. coli and related bacteria constitute about 0.1% of gut flora, and fecal–oral transmission is the major route through which pathogenic strains of the bacterium cause disease. Cells are able to survive outside the body for a limited amount of time, which makes them ideal indicator organisms to test environmental samples for fecal contamination. The bacterium can also be grown easily and inexpensively in a laboratory setting, and has been intensively investigated for over 60 years. E. coli is the most widely studied prokaryotic model organism, and an important species in the fields of biotechnology and microbiology, where it has served as the host organism for the majority of work with recombinant DNA.

German paediatrician and bacteriologist so Theodor Escherich discovered E. coli in 1885, and it is now classified as part of the Enterobacteriaceae family of gamma-proteobacteria.

Serotypes

Pathogenic E.coli strains can be categorized based on elements that can elicit an immune response in animals, namely:

1. O antigen: part of lipopolysaccharide layer
2. K antigen: capsule
3. H antigen: flagellin

For example E.coli strain EDL933 is of the O157:H7 group.

O antigen

The outer membrane of an E. coli cell contains millions of lipopolysaccharide (LPS) molecules, which consists of:

1. O antigen, a polymer of immunogenic repeating oligosaccharides (1–40 units)
2. Core region of phosphorylated nonrepeating oligosaccharides
3. Lipid A (endotoxin)

The O antigen is used for serotyping E.coli and these O group designations go from O1 to O181, with the exception of some groups which have been historically removed, namely O31, O47, O67, O72, O93 (now K84), O94, and O122; groups 174 to 181 are provisional (O174=OX3 and O175=OX7) or are under investigation (176 to 181 are STEC/VTEC). Additionally subtypes exist for many O groups (e.g. O128ab and O128ac). It should be noted though that antibodies towards several O antigens cross-react with other O antigens and partially to K antigens not only from E. coli, but also from other Escherichia species and Enterobacteriaceae species.

The O antigen is encoded by the rfb gene cluster. rol (cld) gene encodes the regulator of lipopolysaccharide O-chain length.

K antigen

The acidic capsular polysaccharide (CPS) is a thick, mucous-like, layer of polysaccharide that surrounds some pathogen E. coli.

There are two separate groups of K-antigen groups, named group I and group II (while a small in-between subset (K3, K10, and K54/K96) has been classified as group III). The former (I) consist of 100 kDa (large) capsular polysaccharides, while the latter (II), associated with extraintestinal diseases, are under 50 kDa in size.

Group I K antigens are only found with certain O-antigens (O8, O9, O20, and O101 groups), they are further subdivided on the basis of absence (IA, similar to that of Klebsiella species in structure) or presence (IB) of amino sugars and some group I K-antigens are attached to the lipid A-core of the lipopolysaccharide (K_LPS), in a similar way to O antigens (and being structurally identical to O antigens in some instances are only considered as K antigens when co-expressed with another authentic O antigen).

Group II K antigens closely resemble those in gram-positive bacteria and greatly differ in composition and are further subdivided according to their acidic components, generally 20–50% of the CPS chains are bound to phospholipids.

In total there are 60 different K antigens that have been recognized (K1, K2a/ac, K3, K4, K5, K6, K7 (=K56), K8, K9 (=O104), K10, K11, K12 (K82), K13(=K20 and =K23), K14, K15, K16, K18a, K18ab (=K22), K19,K24, K26, K27, K28, K29, K30, K31, K34, K37, K39, K40, K41,K42, K43, K44, K45, K46, K47, K49 (O46), K50, K51, K52, K53, K54 (=K96), K55, K74, K84, K85ab/ac (=O141), K87 (=O32), K92, K93, K95, K97, K98, K100, K101, K102, K103, KX104, KX105,and KX106).

H antigen

The H antigen is a major component of flagella, involved in E. coli movement. It is generally encoded by the fliC gene.

There are 53 identified H antigens, numbered from H1 to H56 (H13 and H22 were not E. coli antigens but from Citrobacter freundii, and H50 was found to be the same as H10).

Role in disease

In humans and in domestic animals, virulent strains of E. coli can cause various diseases.

In humans : gastroenteritis, urinary tract infections, and neonatal meningitis. In rarer cases, virulent strains are also responsible for haemolytic-uremic syndrome, peritonitis, mastitis, septicaemia and gram-negative pneumonia.

Gastrointestinal infection

Certain strains of E. coli, such as O157:H7, O104:H4, O121, O26, O103, O111, O145, and O104:H21, produce potentially lethal toxins. Food poisoning caused by E. coli can result from eating unwashed vegetables or poorly butchered and undercooked meat. O157:H7 is also notorious for causing serious and even life-threatening complications such as hemolytic-uremic syndrome. This particular strain is linked to the 2006 United States E. coli outbreak due to fresh spinach. The O104:H4 strain is equally virulent. Antibiotic and supportive treatment protocols for it are not as well-developed (it has the ability to be very enterohemorrhagic like O157:H7, causing bloody diarrhea, but also is more enteroaggregative, meaning it adheres well and clumps to intestinal membranes). It is the strain behind the deadly June 2011 E. coli outbreak in Europe. Severity of the illness varies considerably; it can be fatal, particularly to young children, the elderly or the immunocompromised, but is more often mild. Earlier, poor hygienic methods of preparing meat in Scotland killed seven people in 1996 due to E. coli poisoning, and left hundreds more infected. E. coli can harbour both heat-stable and heat-labile enterotoxins. The latter, termed LT, contain one A subunit and five B subunits arranged into one holotoxin, and are highly similar in structure and function to cholera toxins. The B subunits assist in adherence and entry of the toxin into host intestinal cells, while the A subunit is cleaved and prevents cells from absorbing water, causing diarrhea. LT is secreted by the Type 2 secretion pathway.

If E. coli bacteria escape the intestinal tract through a perforation (for example from an ulcer, a ruptured appendix, or due to a surgical error) and enter the abdomen, they usually cause peritonitis that can be fatal without prompt treatment. However, E. coli are extremely sensitive to such antibiotics as streptomycin or gentamicin. Recent research suggests treatment of enteropathogenic E. coli with antibiotics may not improve the outcome of the disease, as it may significantly increase the chance of developing haemolytic-uremic syndrome.

Intestinal mucosa-associated E. coli are observed in increased numbers in the inflammatory bowel diseases, Crohn's disease and ulcerative colitis. Invasive strains of E. coli exist in high numbers in the inflamed tissue, and the number of bacteria in the inflamed regions correlates to the severity of the bowel inflammation.

Virulence properties

Enteric E. coli (EC) are classified on the basis of serological characteristics and virulence properties. Virotypes include:

Epidemiology of gastrointestinal infection

Transmission of pathogenic E. coli often occurs via fecal–oral transmission. Common routes of transmission include: unhygienic food preparation, farm contamination due to manure fertilization, irrigation of crops with contaminated greywater or raw sewage, feral pigs on cropland, or direct consumption of sewage-contaminated water. Dairy and beef cattle are primary reservoirs of E. coli O157:H7, and they can carry it asymptomatically and shed it in their feces. Food products associated with E. coli outbreaks include cucumber, raw ground beef, raw seed sprouts or spinach, raw milk, unpasteurized juice, unpasteurized cheese and foods contaminated by infected food workers via fecal–oral route.

According to the U.S. Food and Drug Administration, the fecal-oral cycle of transmission can be disrupted by cooking food properly, preventing cross-contamination, instituting barriers such as gloves for food workers, instituting health care policies so food industry employees seek treatment when they are ill, pasteurization of juice or dairy products and proper hand washing requirements.

Shiga toxin-producing E. coli (STEC), specifically serotype O157:H7, have also been transmitted by flies, as well as direct contact with farm animals, petting zoo animals, and airborne particles found in animal-rearing environments.

Urinary tract infection

Uropathogenic E. coli (UPEC) is responsible for approximately 90% of urinary tract infections (UTI) seen in individuals with ordinary anatomy. In ascending infections, fecal bacteria colonize the urethra and spread up the urinary tract to the bladder as well as to the kidneys (causing pyelonephritis), or the prostate in males. Because women have a shorter urethra than men, they are 14 times more likely to suffer from an ascending UTI.

Uropathogenic E. coli use P fimbriae (pyelonephritis-associated pili) to bind urinary tract urothelial cells and colonize the bladder. These adhesins specifically bind D-galactose-D-galactose moieties on the P blood-group antigen of erythrocytes and uroepithelial cells. Approximately 1% of the human population lacks this receptor, and its presence or absence dictates an individual's susceptibility or non-susceptibility, respectively, to E. coli urinary tract infections. Uropathogenic E. coli produce alpha- and beta-hemolysins, which cause lysis of urinary tract cells.

Another virulence factor commonly present in UPEC is the Dr family of adhesins, which are particularly associated with cystitis and pregnancy-associated pyelonephritis. The Dr adhesins bind Dr blood group antigen (Dr) which is present on decay accelerating factor (DAF) on erythrocytes and other cell types. There, the Dr adhesins induce the development of long cellular extensions that wrap around the bacteria, accompanied by the activation of several signal transduction cascades, including activation of PI-3 kinase.

UPEC can evade the body's innate immune defences (e.g. the complement system) by invading superficial umbrella cells to form intracellular bacterial communities (IBCs). They also have the ability to form K antigen, capsular polysaccharides that contribute to biofilm formation. Biofilm-producing E. coli are recalcitrant to immune factors and antibiotic therapy, and are often responsible for chronic urinary tract infections. K antigen-producing E. coli infections are commonly found in the upper urinary tract.

Descending infections, though relatively rare, occur when E. coli cells enter the upper urinary tract organs (kidneys, bladder or ureters) from the blood stream.

Neonatal meningitis (NMEC)

It is produced by a serotype of Escherichia coli that contains a capsular antigen called K1. The colonization of the newborn's intestines with these strains, that are present in the mother's vagina, lead to bacteremia, which leads to meningitis. And because of the absence of the IgM antibodies from the mother (these do not cross the placenta because FcRn only mediates the transfer of IgG), plus the fact that the body recognizes as self the K1 antigen, as it resembles the cerebral glycopeptides, this leads to a severe meningitis in the neonates.

Involvement in cancer or cellular senescence

There are some E. coli strains that contain a polyketide synthase genomic island (pks) whose function is to encode a multi-enzymatic machinery that produces a genotoxic substance, named colibactin. Colibactin can cause cellular senescence or cancer by damaging DNA. However, the mucosal barrier prevents E. coli from reaching the surface of enterocytes. Only when some inflammatory lesion co-occurs with E. coli infection the bacterium is able to inject colibactin to enterocytes inducing tumorogenesis.

Animal diseases

In animals, virulent strains of E. coli are responsible of a variety of diseases, among others septicemia and diarrhea in newborn calves, acute mastitis in dairy cows, colibacillosis also associated with chronic respiratory disease with Mycoplasma where it causes perihepatitis, pericarditis, septicaemic lungs, peritonitis etc. in poultry, and Alabama rot in dogs.

Most of the serotypes isolated from poultry are pathogenic only for birds. So avian sources of E. coli do not seem to be important sources of infections in other animals.

• Colibacillosis in broiler
• Mastitis in cows

Laboratory diagnosis

In stool samples, microscopy will show gram-negative rods, with no particular cell arrangement. Then, either MacConkey agar or EMB agar (or both) are inoculated with the stool. On MacConkey agar, deep red colonies are produced, as the organism is lactose-positive, and fermentation of this sugar will cause the medium's pH to drop, leading to darkening of the medium. Growth on EMB agar produces black colonies with a greenish-black metallic sheen. This is diagnostic of E. coli. The organism is also lysine positive, and grows on TSI slant with a (A/A/g+/H₂S-) profile. Also, IMViC is {+ + – -} for E. coli; as it is indole-positive (red ring) and methyl red-positive (bright red), but VP-negative (no change-colourless) and citrate-negative (no change-green colour). Tests for toxin production can use mammalian cells in tissue culture, which are rapidly killed by shiga toxin. Although sensitive and very specific, this method is slow and expensive.

Typically, diagnosis has been done by culturing on sorbitol-MacConkey medium and then using typing antiserum. However, current latex assays and some typing antisera have shown cross reactions with non-E. coli O157 colonies. Furthermore, not all E. coli O157 strains associated with HUS are nonsorbitol fermentors.

The Council of State and Territorial Epidemiologists recommend that clinical laboratories screen at least all bloody stools for this pathogen. The U.S. Centers for Disease Control and Prevention recommend that "all stools submitted for routine testing from patients with acute community-acquired diarrhea (regardless of patient age, season of the year, or presence or absence of blood in the stool) be simultaneously cultured for E. coli O157:H7 (O157 STEC) and tested with an assay that detects Shiga toxins to detect non-O157 STEC".

Antibiotic therapy and resistance

Bacterial infections are usually treated with antibiotics. However, the antibiotic sensitivities of different strains of E. coli vary widely. As gram-negative organisms, E. coli are resistant to many antibiotics that are effective against gram-positive organisms. Antibiotics which may be used to treat E. coli infection include amoxicillin, as well as other semisynthetic penicillins, many cephalosporins, carbapenems, aztreonam, trimethoprim-sulfamethoxazole, ciprofloxacin, nitrofurantoin and the aminoglycosides.

Antibiotic resistance is a growing problem. Some of this is due to overuse of antibiotics in humans, but some of it is probably due to the use of antibiotics as growth promoters in animal feeds. A study published in the journal Science in August 2007 found the rate of adaptative mutations in E. coli is "on the order of 10 per genome per generation, which is 1,000 times as high as previous estimates," a finding which may have significance for the study and management of bacterial antibiotic resistance.

Antibiotic-resistant E. coli may also pass on the genes responsible for antibiotic resistance to other species of bacteria, such as Staphylococcus aureus, through a process called horizontal gene transfer. E. coli bacteria often carry multiple drug-resistance plasmids, and under stress, readily transfer those plasmids to other species. Indeed, E. coli is a frequent member of biofilms, where many species of bacteria exist in close proximity to each other. This mixing of species allows E. coli strains that are piliated to accept and transfer plasmids from and to other bacteria. Thus, E. coli and the other enterobacteria are important reservoirs of transferable antibiotic resistance.

Beta-lactamase strains

Resistance to beta-lactam antibiotics has become a particular problem in recent decades, as strains of bacteria that produce extended-spectrum beta-lactamases have become more common. These beta-lactamase enzymes make many, if not all, of the penicillins and cephalosporins ineffective as therapy. Extended-spectrum beta-lactamase–producing E. coli (ESBL E. coli) are highly resistant to an array of antibiotics, and infections by these strains are difficult to treat. In many instances, only two oral antibiotics and a very limited group of intravenous antibiotics remain effective. In 2009, a gene called New Delhi metallo-beta-lactamase (shortened NDM-1) that even gives resistance to intravenous antibiotic carbapenem, were discovered in India and Pakistan on E. coli bacteria.

Increased concern about the prevalence of this form of "superbug" in the United Kingdom has led to calls for further monitoring and a UK-wide strategy to deal with infections and the deaths. Susceptibility testing should guide treatment in all infections in which the organism can be isolated for culture.

Phage therapy

Phage therapy—viruses that specifically target pathogenic bacteria—has been developed over the last 80 years, primarily in the former Soviet Union, where it was used to prevent diarrhea caused by E. coli. Presently, phage therapy for humans is available only at the Phage Therapy Center in the Republic of Georgia and in Poland. However, on January 2, 2007, the United States FDA gave Omnilytics approval to apply its E. coli O157:H7 killing phage in a mist, spray or wash on live animals that will be slaughtered for human consumption. The enterobacteria phage T4, a highly studied phage, targets E. coli for infection.

Vaccination

Researchers have actively been working to develop safe, effective vaccines to lower the worldwide incidence of E. coli infection. In March 2006, a vaccine eliciting an immune response against the E. coli O157:H7 O-specific polysaccharide conjugated to recombinant exotoxin A of Pseudomonas aeruginosa (O157-rEPA) was reported to be safe in children two to five years old. Previous work had already indicated it was safe for adults. A phase III clinical trial to verify the large-scale efficacy of the treatment is planned.

In 2006, Fort Dodge Animal Health (Wyeth) introduced an effective, live, attenuated vaccine to control airsacculitis and peritonitis in chickens. The vaccine is a genetically modified avirulent vaccine that has demonstrated protection against O78 and untypeable strains.

In January 2007, the Canadian biopharmaceutical company Bioniche announced it has developed a cattle vaccine which reduces the number of O157:H7 shed in manure by a factor of 1000, to about 1000 pathogenic bacteria per gram of manure.

In April 2009, a Michigan State University researcher announced he had developed a working vaccine for a strain of E. coli. Dr. Mahdi Saeed, Professor of epidemiology and infectious disease in MSU's colleges of Veterinary Medicine and Human Medicine, has applied for a patent for his discovery and has made contact with pharmaceutical companies for commercial production.

See also

• List of strains of Escherichia coli

References

1. "Escherichia coli O157:H7". CDC Division of Bacterial and Mycotic Diseases. Retrieved 2011-04-19.
2. Vogt RL, Dippold L (2005). "Escherichia coli O157:H7 outbreak associated with consumption of ground beef, June–July 2002". Public Health Rep. 120 (2): 174–8. PMC 1497708. PMID 15842119.
3. Bentley R, Meganathan R (1 September 1982). "Biosynthesis of vitamin K (menaquinone) in bacteria". Microbiol. Rev. 46 (3): 241–80. PMC 281544. PMID 6127606.
4. Hudault S, Guignot J, Servin AL (July 2001). "Escherichia coli strains colonising the gastrointestinal tract protect germfree mice against Salmonella typhimurium infection". Gut. 49 (1): 47–55. doi:10.1136/gut.49.1.47. PMC 1728375. PMID 11413110.{{cite journal}}: CS1 maint: multiple names: authors list (link)
5. Reid G, Howard J, Gan BS (September 2001). "Can bacterial interference prevent infection?". Trends Microbiol. 9 (9): 424–428. doi:10.1016/S0966-842X(01)02132-1. PMID 11553454.{{cite journal}}: CS1 maint: multiple names: authors list (link)
6. Eckburg PB; Bik EM; Bernstein CN; Purdom E; Dethlefsen L; et al. (2005). "Diversity of the human intestinal microbial flora". Science. 308 (5728): 1635–1638. doi:10.1126/science.1110591. PMC 1395357. PMID 15831718. {{cite journal}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)
7. ^ Feng P, Weagant S, Grant, M (2002-09-01). "Enumeration of Escherichia coli and the Coliform Bacteria". Bacteriological Analytical Manual (8th ed.). FDA/Center for Food Safety & Applied Nutrition. Retrieved 2007-01-25.{{cite web}}: CS1 maint: multiple names: authors list (link)
8. Thompson, Andrea (2007-06-04). "E. coli Thrives in Beach Sands". Live Science. Retrieved 2007-12-03.
9. "Escherichia". Taxonomy Browser. NCBI. Retrieved 2007-11-30.
10. ^ Don J. Brenner, Noel R. Krieg, James T. Staley (July 26, 2005) . George M. Garrity (ed.). The Gammaproteobacteria. Bergey's Manual of Systematic Bacteriology. Vol. 2B (2nd ed.). New York: Springer. p. 1108. ISBN 978-0-387-24144-9. British Library no. GBA561951.{{cite book}}: CS1 maint: multiple names: authors list (link)
11. Wang L; Rothemund D; Reeves PR (May 2003). "Species-Wide Variation in the Escherichia coli Flagellin (H-Antigen) Gene". Journal of Bacteriology. 185 (9): 2396–2943. doi:10.1128/JB.185.9.2936-2943.2003. PMC 154406.
12. ^ Todar, K. "Pathogenic E. coli". Online Textbook of Bacteriology. University of Wisconsin–Madison Department of Bacteriology. Retrieved 2007-11-30.
13. Tauschek M, Gorrell R, Robins-Browne RM,. "Identification of a protein secretory pathway for the secretion of heat-labile enterotoxin by an enterotoxigenic strain of Escherichia coli". PNAS. 99 (10): 7066–71. doi:10.1073/pnas.092152899. PMC 124529. PMID 12011463.{{cite journal}}: CS1 maint: extra punctuation (link) CS1 maint: multiple names: authors list (link)
14. Wong CS, Jelacic S, Habeeb RL; et al. (29 June 2000). "The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections". N Engl J Med. 342 (26): 1930–6. doi:10.1056/NEJM200006293422601. PMC 3659814. PMID 10874060.{{cite journal}}: CS1 maint: multiple names: authors list (link)
15. Rolhion N, Darfeuille-Michaud A (2007). "Adherent-invasive Escherichia coli in inflammatory bowel disease". Inflamm. Bowel Dis. 13 (10): 1277–1283. doi:10.1002/ibd.20176. PMID 17476674.
16. Baumgart M; Dogan B; Rishniw M; et al. (2007). "Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum". ISME J. 1 (5): 403–418. doi:10.1038/ismej.2007.52. PMID 18043660. {{cite journal}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)
17. "World Health Organization. Enterotoxigenic ''Escherichia coli'' (ETEC)". Who.int. 2010-12-08. Retrieved 2011-06-05.
18. Rendón, M. A.; et al. (2007). "Commensal and pathogenic Escherichia coli use a common pilus adherence factor for epithelial cell colonization". PNAS. 104 (25): 10637–10642. doi:10.1073/pnas.0704104104. PMC 1890562. PMID 17563352.
19. Rolhion N, Darfeuille-Michaud A. (2007). "Adherent-invasive Escherichia coli in inflammatory bowel disease". Inflamm Bowel Dis. 13 (10): 1277–83. PMID 17476674. {{cite journal}}: Vancouver style error: punctuation in name 2 (help)
20. Evans Jr., Doyle J.; Dolores G. Evans. "Escherichia Coli". Medical Microbiology, 4th edition. The University of Texas Medical Branch at Galveston. Archived from the original on 2007-11-02. Retrieved 2007-12-02.
21. ^ "Retail Establishments; Annex 3 – Hazard Analysis". Managing Food Safety: A Manual for the Voluntary Use of HACCP Principles for Operators of Food Service and Retail Establishments. U.S. Department of Health and Human Services Food and Drug Administration Center for Food Safety and Applied Nutrition. April 2006. Archived from the original on 2007-06-07. Retrieved 2007-12-02.
22. Gehlbach, S.H.; J.N. MacCormack, B.M. Drake, W.V. Thompson (April 1973). "Spread of disease by fecal-oral route in day nurseries". Health Service Reports. 88 (4): 320–322. doi:10.2307/4594788. JSTOR 4594788. PMC 1616047. PMID 4574421.{{cite journal}}: CS1 maint: multiple names: authors list (link)
23. ^ Sabin Russell (October 13, 2006). "Spinach E. coli linked to cattle; Manure on pasture had same strain as bacteria in outbreak". San Francisco Chronicle. Retrieved 2007-12-02.
24. Heaton JC, Jones K (March 2008). "Microbial contamination of fruit and vegetables and the behaviour of enteropathogens in the phyllosphere: a review". J. Appl. Microbiol. 104 (3): 613–626. doi:10.1111/j.1365-2672.2007.03587.x. PMID 17927745.
25. Thomas R. DeGregori (2007-08-17). "CGFI: Maddening Media Misinformation on Biotech and Industrial Agriculture". Retrieved 2007-12-08.
26. Chalmers, R.M.; H. Aird, F.J. Bolton (2000). "Waterborne Escherichia coli O157". Society for Applied Microbiology Symposium Series (29): 124S–132S. PMID 10880187.
27. ^ Bach, S.J.; T.A. McAllister, D.M. Veira, V.P.J. Gannon, and R.A. Holley (2002). "Transmission and control of Escherichia coli O157:H7". Canadian Journal of Animal Science. 82 (4): 475–490. doi:10.4141/A02-021.{{cite journal}}: CS1 maint: multiple names: authors list (link)
28. "Germany: Ten die from E.coli-infected cucumbers". BBC. 28 May 2011. Retrieved 28 May 2011.
29. Institute of Medicine of the National Academies; Committee on the Review of the USDA E. coli O157:H7 Farm-to-Table Process Risk Assessment, Board on Health Promotion and Disease Prevention Food and Nutrition Board, Institute of Medicine of the National Academies. (2002). Escherichia coli O157:H7 in Ground Beef: Review of a Draft Risk Assessment. Washington, D.C.: The National Academies Press. ISBN 0-309-08627-2.{{cite book}}: CS1 maint: multiple names: authors list (link) CS1 maint: numeric names: authors list (link)
30. Szalanski A, Owens C, McKay T, Steelman C (2004). "Detection of Campylobacter and Escherichia coli O157:H7 from filth flies by polymerase chain reaction". Med Vet Entomol. 18 (3): 241–6. doi:10.1111/j.0269-283X.2004.00502.x. PMID 15347391.{{cite journal}}: CS1 maint: multiple names: authors list (link)
31. Sela S, Nestel D, Pinto R, Nemny-Lavy E, Bar-Joseph M (2005). "Mediterranean fruit fly as a potential vector of bacterial pathogens". Appl Environ Microbiol. 71 (7): 4052–6. doi:10.1128/AEM.71.7.4052-4056.2005. PMC 1169043. PMID 16000820.{{cite journal}}: CS1 maint: multiple names: authors list (link)
32. Alam M, Zurek L (2004). "Association of Escherichia coli O157:H7 with houseflies on a cattle farm". Appl Environ Microbiol. 70 (12): 7578–80. doi:10.1128/AEM.70.12.7578-7580.2004. PMC 535191. PMID 15574966.
33. Rahn, K.; S.A. Renwick, R.P. Johnson, J.B. Wilson, R.C. Clarke, D. Alves, S.A. McEwen, H. Lior, J. Spika (April 1998). "Follow-up study of verocytotoxigenic Escherichia coli infection in dairy farm families". Journal of Infectious Disease. 177 (4): 1139–1139. doi:10.1086/517394. PMID 9535003.{{cite journal}}: CS1 maint: multiple names: authors list (link)
34. Trevena, W.B.; G.A Willshaw, T. Cheasty, G. Domingue, C. Wray (December 1999). "Transmission of Vero cytotoxin producing Escherichia coli O157 infection from farm animals to humans in Cornwall and west Devon". Community Disease and Public Health. 2 (4): 263–8. PMID 10598383.{{cite journal}}: CS1 maint: multiple names: authors list (link)
35. Heuvelink, A.E.; C. van Heerwaarden, J.T. Zwartkruis-Nahuis, R. van Oosterom, K. Edink, Y.T. van Duynhoven and E. de Boer (October 2002). "Escherichia coli O157 infection associated with a petting zoo". Epidemiology and Infection. 129 (2): 295–302. doi:10.1017/S095026880200732X. PMC 2869888. PMID 12403105.{{cite journal}}: CS1 maint: multiple names: authors list (link)
36. Varma, J.K.; K.D. Greene, M.E. Reller, S.M. DeLong, J. Trottier, S.F. Nowicki, M. DiOrio, E.M. Koch, T.L. Bannerman, S.T. York, M.A. Lambert-Fair, J.G. Wells, P.S. Mead (November 26, 2003). "An outbreak of Escherichia coli O157 infection following exposure to a contaminated building". JAMA. 290 (20): 2709–2712. doi:10.1001/jama.290.20.2709. PMID 14645313.{{cite journal}}: CS1 maint: multiple names: authors list (link)
37. Nicolle LE (February 2008). "Uncomplicated urinary tract infection in adults including uncomplicated pyelonephritis". Urol. Clin. North Am. 35 (1): 1–12. doi:10.1016/j.ucl.2007.09.004. PMID 18061019.
38. ^ Identified Virulence Factors of UPEC : Adherence, State Key Laboratory for Moleclular Virology and Genetic Engineering, Beijing. Retrieved July 2011
39. Justice S, Hunstad D, Seed P, Hultgren S (2006). "Filamentation by Escherichia coli subverts innate defenses during urinary tract infection". Proc Natl Acad Sci U S A. 103 (52): 19884–9. doi:10.1073/pnas.0606329104. PMC 1750882. PMID 17172451.{{cite journal}}: CS1 maint: multiple names: authors list (link)
40. Ehrlich G, Hu F, Shen K, Stoodley P, Post J (August 2005). "Bacterial plurality as a general mechanism driving persistence in chronic infections". Clin Orthop Relat Res (437): 20–4. doi:10.1097/00003086-200508000-00005. PMC 1351326. PMID 16056021.{{cite journal}}: CS1 maint: multiple names: authors list (link)
41. Secher T, Samba-Louaka A, Oswald E, Nougayrède JP (2013). "Escherichia coli producing colibactin triggers premature and transmissible senescence in mammalian cells". PLOS ONE. 8 (10): e77157. doi:10.1371/journal.pone.0077157. PMC 3792898. PMID 24116215.{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: unflagged free DOI (link)
42. Cuevas-Ramos G, Petit CR, Marcq I, Boury M, Oswald E, Nougayrède JP (2010). "Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells". Proceedings of the National Academy of Sciences of the United States of America. 107 (25): 11537–11542. doi:10.1073/pnas.1001261107. PMC 2895108. PMID 20534522.{{cite journal}}: CS1 maint: multiple names: authors list (link)
43. Arthur, Janelle C.; et al. (5 October 2012). "Intestinal Inflammation Targets Cancer-Inducing Activity of the Microbiota". Science. 338. doi:10.1126/science.1224820.
44. W.B. Gross (1978), Colibacillosis, in "Diseases of poultry", ed. by M.S. Hofstad, Iowa State University Press, Ames, Iowa, USA; 8th ed. ISBN 0-8138-0430-2, p. 270
45. Paton JC, Paton AW (1 July 1998). "Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections". Clin. Microbiol. Rev. 11 (3): 450–79. PMC 88891. PMID 9665978.
46. "Importance of Culture Confirmation of Shiga Toxin-producing Escherichia coli Infection as Illustrated by Outbreaks of Gastroenteritis --- New York and North Carolina, 2005". MMWR. CDC. Retrieved 19 July 2011.
47. "Recommendations for Diagnosis of Shiga Toxin--Producing Escherichia coli Infections by Clinical Laboratories". MMWR Recommendations and Reports. CDC (USA). Retrieved 19 July 2011.
48. Johnson J, Kuskowski M, Menard M, Gajewski A, Xercavins M, Garau J (2006). "Similarity between human and chicken Escherichia coli isolates in relation to ciprofloxacin resistance status". J Infect Dis. 194 (1): 71–8. doi:10.1086/504921. PMID 16741884.{{cite journal}}: CS1 maint: multiple names: authors list (link)
49. Perfeito, Lília; Fernandes, Lisete; Mota, Catarina; Gordo, Isabel (2007). "Adaptive Mutations in Bacteria: High Rate and Small Effects". Science. 317 (5839): 813–815. doi:10.1126/science.1142284.
50. Salyers AA, Gupta A, Wang Y (2004). "Human intestinal bacteria as reservoirs for antibiotic resistance genes". Trends Microbiol. 12 (9): 412–6. doi:10.1016/j.tim.2004.07.004. PMID 15337162.{{cite journal}}: CS1 maint: multiple names: authors list (link)
51. Paterson DL, Bonomo RA (2005). "Extended-spectrum beta-lactamases: a clinical update". Clin. Microbiol. Rev. 18 (4): 657–86. doi:10.1128/CMR.18.4.657-686.2005. PMC 1265908. PMID 16223952.
52. "HPA Press Statement: Infections caused by ESBL-producing E. coli".
53. "Therapeutic use of bacteriophages in bacterial infections". Polish Academy of Sciences.
54. "Medical conditions treated with phage therapy". Phage Therapy Center.
55. "OmniLytics Announces USDA/FSIS Approval for Bacteriophage Treatment of E. coli O157:H7 on Livestock". OmniLytics.
56. Girard M, Steele D, Chaignat C, Kieny M (2006). "A review of vaccine research and development: human enteric infections". Vaccine. 24 (15): 2732–50. doi:10.1016/j.vaccine.2005.10.014. PMID 16483695.{{cite journal}}: CS1 maint: multiple names: authors list (link)
57. ^ Ahmed A, Li J, Shiloach Y, Robbins J, Szu S (2006). "Safety and immunogenicity of Escherichia coli O157 O-specific polysaccharide conjugate vaccine in 2-5-year-old children". J Infect Dis. 193 (4): 515–21. doi:10.1086/499821. PMID 16425130.{{cite journal}}: CS1 maint: multiple names: authors list (link)
59. Pearson H (2007). "The dark side of E. coli". Nature. 445 (7123): 8–9. doi:10.1038/445008a. PMID 17203031.
60. "New cattle vaccine controls E. coli infections". Canada AM. 2007-01-11. Retrieved 2007-02-08.
61. "Canadian Research Collaboration Produces World's First Food Safety Vaccine: Against E. coli O157:H7" (Press release). Bioniche Life Sciences Inc. 2007-01-10. Retrieved 2007-02-08.
62. "Researchers develop E. coli vaccine". Physorg.com. Retrieved 2011-06-05.

• Escherichia coli
• Rabbit diseases
• Pathogenic bacteria